ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.150,71
-0,10%
S&P 500
5.303,27
0,12%
US Dollar vs BRL
5,1047
0,00%
Bitcoin
66.929,93
-0,22%
Brent Oil
83,76
0,00%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Heron Therapeautics Inc (HRTX)

  7. Heron Therapeautics Inc (HRTX) Notícias

HRTX

Heron Therapeautics (HRTX)

Heron Therapeautics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:HRTX
DataHoraFonteTítuloCódigoCompanhia
07/05/202409:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:HRTXHeron Therapeautics Inc
07/05/202409:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:HRTXHeron Therapeautics Inc
07/05/202409:00PR Newswire (US)Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate UpdatesNASDAQ:HRTXHeron Therapeautics Inc
24/04/202409:00PR Newswire (US)Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024NASDAQ:HRTXHeron Therapeautics Inc
11/04/202417:05PR Newswire (US)Heron Therapeutics to Host Investor Day on May 15, 2024 in New York CityNASDAQ:HRTXHeron Therapeautics Inc
28/03/202417:05PR Newswire (US)Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:HRTXHeron Therapeautics Inc
13/03/202417:25AllPennyStocks.comBiotech Finds Mid-Week Success Following Q4 Earnings ReleaseNASDAQ:HRTXHeron Therapeautics Inc
12/03/202417:05PR Newswire (US)Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate UpdatesNASDAQ:HRTXHeron Therapeautics Inc
12/03/202408:22IH Market NewsGlobal Markets Await U.S. Inflation Report: Mixed Movements in Pre-Market TradingNASDAQ:HRTXHeron Therapeautics Inc
28/02/202410:00PR Newswire (US)Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024NASDAQ:HRTXHeron Therapeautics Inc
14/02/202418:37Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:HRTXHeron Therapeautics Inc
24/01/202411:25AllPennyStocks.comPremarket Heats Up For Biotech Before Opening BellNASDAQ:HRTXHeron Therapeautics Inc
23/01/202422:00PR Newswire (US)Heron Therapeutics Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue ProceduresNASDAQ:HRTXHeron Therapeautics Inc
19/01/202423:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:HRTXHeron Therapeautics Inc
07/01/202419:00PR Newswire (US)Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative PainNASDAQ:HRTXHeron Therapeautics Inc
15/11/202314:25AllPennyStocks.comBiotech Shares Up Sharply Following Quarterly ResultsNASDAQ:HRTXHeron Therapeautics Inc
14/11/202318:05PR Newswire (US)Heron Therapeutics Announces Third Quarter 2023 Financial Results and Updates Financial GuidanceNASDAQ:HRTXHeron Therapeautics Inc
07/11/202318:05PR Newswire (US)Heron Therapeutics to Report Third Quarter 2023 Financial Results On Tuesday, November 14, 2023NASDAQ:HRTXHeron Therapeautics Inc
23/08/202317:08Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:HRTXHeron Therapeautics Inc
14/08/202317:05PR Newswire (US)Heron Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate UpdatesNASDAQ:HRTXHeron Therapeautics Inc
07/08/202317:05PR Newswire (US)Heron Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023NASDAQ:HRTXHeron Therapeautics Inc
01/08/202314:56Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:HRTXHeron Therapeautics Inc
25/07/202317:15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:HRTXHeron Therapeautics Inc
25/07/202317:13Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:HRTXHeron Therapeautics Inc
24/07/202310:02PR Newswire (US)Heron Therapeutics Announces Cost Reduction Plan and RestructuringNASDAQ:HRTXHeron Therapeautics Inc
24/07/202310:00PR Newswire (US)Heron Therapeutics Announces $30 Million Private Placement FinancingNASDAQ:HRTXHeron Therapeautics Inc
30/06/202317:06Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:HRTXHeron Therapeautics Inc
23/06/202317:29Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:HRTXHeron Therapeautics Inc
23/06/202317:19Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:HRTXHeron Therapeautics Inc
23/06/202317:05PR Newswire (US)Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial OfficerNASDAQ:HRTXHeron Therapeautics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:HRTX

Seu Histórico Recente

LSE
XGLF
Xgcc Select Sw
LSE
0L12
Spdr S&p Oil & Gas Equip...
NYSE
WLS
William Lyon
NASDAQ
DTUL
Barclays Bank PLC
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados